Ruutu T, Elonen E
Third Department of Medicine, University of Helsinki, Finland.
Hematol Oncol. 1991 Mar-Apr;9(2):87-92. doi: 10.1002/hon.2900090204.
Twenty patients with advanced acute leukemia (16 acute myeloid leukemia (AML), three myeloid blast crisis (BC) of chronic myeloid leukemia (CML), one acute lymphatic leukemia) were treated with a peroral regimen consisting of etoposide 80 mg/m2 and 6-thioguanine 100 mg/m2 twice daily for 5 days, and idarubicin 15 mg/m2 once daily for 3 days (ETI). Two AML patients were in first relapse. All the other patients with acute leukemia had a later relapse or were refractory to primary or salvage treatment. One to six ETI cycles were given. Four AML patients achieved remission and one patient with BC of CML entered the second chronic phase. Clearing of the blood of leukemic cells was seen in seven additional patients. Infection was the most common complication, gastrointestinal toxicity was not a major problem. In conclusion, peroral ETI treatment has a marked antileukemic effect even in an advanced disease, and the toxicity is moderate and well acceptable.
20例晚期急性白血病患者（16例急性髓系白血病（AML）、3例慢性髓系白血病（CML）的髓系原始细胞危象（BC）、1例急性淋巴细胞白血病）接受了口服方案治疗，该方案包括依托泊苷80mg/m²和6-硫鸟嘌呤100mg/m²，每日2次，共5天，以及去甲氧柔红霉素15mg/m²，每日1次，共3天（ETI）。2例AML患者处于首次复发期。所有其他急性白血病患者均有较晚复发或对初始或挽救治疗耐药。给予1至6个ETI疗程。4例AML患者获得缓解，1例CML的BC患者进入第二次慢性期。另外7例患者出现白血病细胞血液清除。感染是最常见的并发症，胃肠道毒性不是主要问题。总之，口服ETI治疗即使在晚期疾病中也有显著的抗白血病作用，且毒性中等，易于接受。
